A5088210913- Treatment of Major Depression
- Tryptophan and brain disorders
- Electroconvulsive Therapy Studies
- Sleep and related disorders
- Mental Health Research Topics
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Alcoholism and Thiamine Deficiency
- Stress Responses and Cortisol
- Schizophrenia research and treatment
- Child and Adolescent Psychosocial and Emotional Development
- Mental Health and Psychiatry
- Genetics and Neurodevelopmental Disorders
- Sleep and Wakefulness Research
- Attention Deficit Hyperactivity Disorder
- Digital Mental Health Interventions
- Geomagnetism and Paleomagnetism Studies
- Bipolar Disorder and Treatment
- Functional Brain Connectivity Studies
- Historical and Archaeological Studies
- Mental Health Treatment and Access
- Memory and Neural Mechanisms
Centre Hospitalier Sainte-Anne
2014-2024
Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale
2024
Sorbonne Paris Cité
2012-2019
Université Paris Cité
2012-2019
Délégation Paris 5
2012-2019
Institut de Psychiatrie et Neurosciences de Paris
2014-2019
Inserm
2012-2019
Centre National de la Recherche Scientifique
2018
Ste. Anne's Hospital
2014
Major depressive disorder is a complex multifactorial condition with so far poorly characterized underlying pathophysiology. Consequently, the available treatments are from satisfactory as it estimated that up to 30% of patients resistant conventional treatment. Recent comprehensive evidence has been accumulated which suggests inflammation may be implied in etiology this disease. Here we investigated ketamine an innovative treatment strategy due its immune-modulating capacities. In murine...
Posttraumatic stress disorder (PTSD) is a severe and frequent affection that highly comorbid to major depressive disorder. Comorbid PTSD depression are usually treatment-resistant, with high risk of functional impairment suicide. Esketamine nasal spray recent validated treatment for treatment-resistant (TRD), but its efficacy on TRD-PTSD remains insufficiently documented. In particular, flashbacks can occur during esketamine administration their influence clinical outcomes unknown.
Article Abstract Background: The DSM-IV age at onset criterion for attention-deficit/hyperactivity disorder (ADHD) has been a subject of debate. In DSM-5, the required (ie, by which impairing symptoms must have present) increased from 7 years to 12 years. present study examined measurement properties ADHD according onset. Method: Data were derived 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions, included 34,653 US participants. Among participants with lifetime...
Benzodiazepines should be prescribed on a short‐term basis, but significant proportion of patients (%) use them for more than 6 months, constituting serious public health issue. Indeed, few strategies are effective in helping to discontinue long‐term benzodiazepine treatments. The aim this study was assess the feasibility and impact program including cognitive behavioural therapy, psychoeducation, balneotherapy spa resort facilitate discontinuation benzodiazepines. We conducted prospective...
Objective ESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included from early access program to post-marketing launch.
Benzodiazepines are widely used in France: 11.5 million of consumers (22% with 2 benzodiazepines simultaneously), 131 boxes were sold 2012. Annual length use: anxiolytic 5 months, hypnotic 3.9 months. Risk fall, Road accident, risk Abuse and dependence & possible increase Alzheimer disease. Using the fact that spa center an institutional place not as stigmatizing less regressing than being hospital able to reduce anxiety disorders (STOP TAG study).
Introduction Esketamine nasal spray has been developed to treat adults with treatment resistant depression. On Dec.2019, EMA granted a market access approval in this indication. Objectives ESKALE is descriptive study of depression patients treated esketamine France. Methods Observational retrospective study. 157 are included 3 cohorts depending on their initiation date. This abstract presents the second interim results and whom data collection ranges from Oct.2019 Sept.2021. Results 66.7%...